CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 37-6 - October 12, 2023
- Imprint: Elsevier
- Editors: Caron A Jacobson, Parth S. Shah
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 3 0 0 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 3 0 1 - 0
In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL).
- Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more.
- Provides in-depth clinical reviews on CAR T-cell, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Hematology, oncology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia
- Key points
- Introduction and background
- Discussion
- Summary
- Clinics care points
- Disclosure
- Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
- Key points
- Introduction
- Clinics care points
- Disclosure
- Funding
- Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Key points
- Introduction
- Background
- Chimeric antigen receptor T-cell therapy in indolent B-non-Hodgkin’s lymphoma
- Chimeric antigen receptor T-cell therapy in mantle cell lymphoma
- Chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia
- Discussion
- Chimeric Antigen Receptor T Cells in Multiple Myeloma
- Key points
- Background
- Summary
- Conflicts of interest
- Disclosure
- Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
- Key points
- Introduction
- Chimeric antigen receptor-T cells in Hodgkin lymphoma
- Chimeric antigen receptor-T cells in T-cell lymphoma
- Summary
- Clinics care points
- Conflict of interest
- Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
- Key points
- Introduction
- Background
- Clinical chimeric antigen receptor T-cell platforms in acute myeloid leukemia
- How to reduce on-target toxicity
- How to increase efficacy?
- Summary
- Clinics care points
- Disclosure
- Funding support
- Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
- Key points
- Introduction
- Patient selection
- Challenges to Chimeric Antigen Receptor T-Cells in Solid Tumors
- Advancements in Chimeric Antigen Receptor T-Cell Therapy by Tumor Type
- Summary
- Clinics care points
- Disclosures
- Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
- Key points
- Introduction
- Early toxicities of chimeric antigen receptor T-cells
- Delayed toxicities of chimeric antigen receptor T-cells
- Additional considerations and future directions
- Summary
- Clinics care points
- Disclosures
- Disclaimer
- Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
- Key points
- Background
- Resistance mechanisms
- Summary
- Clinics care points
- Disclosures
- The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
- Key points
- Introduction
- Discussion
- Bispecific antibodies in multiple myeloma
- Summary
- Clinics care points
- Disclosure
- The Future of Chimeric Antigen Receptor T Cell Therapy
- Key points
- Introduction
- Discussion
- Summary
- Funding
- Conflict of Interest
- Edition: 1
- Volume: 37-6
- Published: October 12, 2023
- Imprint: Elsevier
- No. of pages: 240
- Language: English
- Hardback ISBN: 9780443183003
- eBook ISBN: 9780443183010
CJ
Caron A Jacobson
Affiliations and expertise
Harvard Medical SchoolPS
Parth S. Shah
Affiliations and expertise
Assistant Professor of Medicine, Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Director of Genome Informatics, Dartmouth-Hitchcock, Transplant and CAR-T, Dana-Farber Cancer Institute